Background: Initiating antiretroviral therapy (ART) early improves clinical outcomes and prevents transmission. Guidelines for first-line therapy have changed with the availability of newer ART agents. In this study, we compared persistence and virologic responses with initial ART according to the class of anchor agent used.
INTRODUCTION
Initiating antiretroviral therapy (ART) early in HIV infection improves clinical outcomes and prevents transmission. 1,2 US treatment guidelines have changed with the availability of newer ART agents and currently recommend starting ART with a combination of 2 NRTIs, and an integrase strand transfer inhibitor (INSTI), or a boosted protease inhibitor (bPI). 3 The effectiveness of INSTIcontaining regimens compared with previously available regimens has not been well characterized. In this study, we compared response to initial ART in the clinical setting including continuation of the initial regimen, known as persistence or durability, and virologic response.
METHODS
All patients initiating ART in the University of North Carolina (UNC) Center for AIDS Research HIV Clinical Cohort, 1996-2014, were included. This prospective cohort of all primary HIV care patients at the UNC Hospitals is representative of HIV-infected patients in care in North Carolina. 4 Patients were followed from the first ART initiation (baseline) until the first of outcome, loss to follow-up, death, or November 2015. The 2 primary outcomes evaluated were ART discontinuation, defined as change in anchor agent class or stopping ART for longer than 2 weeks, and virologic failure, defined as the first HIV RNA level $400 copies/mL after 24 weeks of therapy in an intention-to-treat approach, where patients lost to follow-up with HIV RNA ,400 copies/mL were censored and changes in therapy were ignored. ART regimen categories were based on anchor agent: INSTI (any INSTI), bPI (ritonavir-boosted atazanavir, darunavir, or lopinavir), non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz, or rilpivirine), other (including unboosted and other bPI), and NRTI (regimens including only NRTIs). Patients provided written informed consent to participate in the clinical cohort, and the UNC Institutional Review Board approved both the cohort study and this secondary data analysis.
Separate time-to-event analyses were performed for each outcome of interest, including Kaplan-Meier survival curves and Cox proportional hazards models adjusted for baseline age, sex, race, CD4 cell count, HIV RNA level, and calendar year. We excluded patients missing baseline CD4 or HIV RNA measurements. In a sensitivity analysis, we included patients missing baseline measurements and used multiple imputations with Markov Chain Monte Carlo and 50 †Race for this study was based on medical record reviews and categorized by the investigators. We assessed race in this study given previous evidence of an association with HIV clinical outcomes.
‡Follow-up years defined as time from ART initiation until the first of death, loss to follow-up (last clinic visit plus 12 months), or administrative censoring (November 2015). §Reasons for discontinuation included virologic failure and stopping ART for more than 2 weeks (23% and 37%, respectively) overall and for INSTI (5% and 54%), NNRTI (18% and 42%), bPI (20% and 35%), other (29% and 35%), and NRTI (29% and 26%).
║Estimates from Cox proportional hazards models. 
RESULTS
A total of 1624 patients who initiated ART between 1996 and 2014 were 28% women, 60% African American, 28% white, and a median of 37 years old at baseline (Table  1) . Eleven percent initiated INSTI, 33% NNRTI, 20% bPI, 27% other, and 9% NRTI only regimens. The most common NRTI backbone combinations were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) among patients on INSTI (92%); FTC/TDF and zidovudine/lamivudine (3TC) among patients on NNRTI (59% and 22%, respectively); and TDF/ FTC, zidovudine/3TC, and abacavir/3TC among patients on bPI (57%, 18%, and 9%, respectively). Patients initiating different ART regimens differed significantly on most baseline characteristics including sex, race, and year of starting ART. Notably, CD4 cell counts were statistically significantly different by ART regimen with a median of 403, 279, 230, 237, and 341 cells/mm 3 for patients starting INSTI, NNRTI, bPI, other, and NRTI regimens, respectively.
Median times to discontinuation and virologic failure for NNRTI patients were 3.5 and 5.1 years, respectively (Fig.  1A-B) , compared with .7.4 years for INSTI patients for each of these events. Among 1111 patients who discontinued ART, 23% and 37% were because of virologic failure and ART interruption, respectively, and this varied with ART regimen. In unadjusted analyses, the estimated hazard ratio (HR) among those initiating an INSTI, as compared to an NNRTI, was 0.48 (95% CI: 0.35 to 0.67) for time to discontinuation and 0.46 (95% CI: 0.31 to 0.67) for time to virologic failure (Table 1) (Fig. 1C-D) . In adjusted models restricted to years 2007-2014 and comparing only INSTI regimens to NNRTI, the HR was 0.52 (0.34 to 0.80) for time to discontinuation and 0.59 (0.34 to 1.03) for time to virologic failure. In this comparison, .90% of both INSTI and NNRTI regimens had TDF/FTC as the NRTI backbone. In a sensitivity analysis including patients missing CD4 and HIV RNA at baseline and using multiple imputation, in adjusted models restricted to 2007-2014 and comparing INSTI regimens (n = 180) with NNRTI (n = 295), the HR was 0.52 (95% CI: 0.34 to 0.79) for time to discontinuation and 0.57 (0.33 to 0.98) for time to virologic failure. Results were similar when follow-up was limited to 3 years after ART initiation, and when NRTI backbone was included as an adjustment variable (results not shown). Patients initiating bPI, other, or NRTI regimens fared worse in time-to-discontinuation and virologic failure analyses than patients initiating an NNRTI.
DISCUSSION
To our knowledge, this study demonstrates for the first time the dramatic increase in initial therapy virologic response and persistence with INSTI-containing regimens. Studies on initial ART duration before the availability of INSTI agents estimated median times on first therapy ranging from 1 to 2.9 years. [5] [6] [7] More recent reports have observed increases in durability with median times from 2.9 to 4.6 years, with patients initiated on NNRTIs remaining on their initial ART longer than those started on bPIs and other agents. 8, 9 In this study, patients started on non-INSTI regimens had first ART durability comparable with these previous reports with similar associations observed between NNRTI and bPI regimens. Notably, we found that patients initiating INSTI-containing regimens remained on their initial regimen at least twice as long on average than patients initiating other types of ART. Our study is the first to examine specifically INSTIcontaining regimens and to focus on changes of anchor class as regimen discontinuation. This definition likely reflects more relevant regimen modifications not related to simplification or to backbone agent changes.
The greater INSTI regimen persistence likely captures the contributions of favorable safety, efficacy, and tolerability profiles of INSTI regimens. Randomized clinical trials of INSTI agents have reported rare drug discontinuations because of adverse events, which were generally mild or moderate and lower than for NNRTI-based regimens and high virologic response rates and low failure rates that were comparable or better than NNRTI. [10] [11] [12] Our findings of INSTI effectiveness from routine clinical care therefore extend these previous results and suggest that more tolerable regimens with high efficacy result in increased initial ART persistence in a real-world setting and with longer observation.
Our findings are limited by smaller sample size and person-time available for INSTI initiators and possible residual confounding because of differences in baseline clinical covariates. In addition, specific reasons for discontinuation were not examined and may have varied across initial ART regimens. This study was also conducted at a single clinical site and, therefore, the generalizability of our results should be considered carefully. The demographic make-up of our clinical site is, however, very similar to the demographics of the HIV epidemic in Southeastern United States. 4 Expanding these analyses to national and international cohort collaborations and including future years of INSTI clinical care experience will be important to confirm these initial findings and inform clinical care practice.
